Stocks and Investing Stocks and Investing
Tue, January 24, 2023
Mon, January 23, 2023

David Amsellem Maintained (SUPN) at Buy with Increased Target to $47 on, Jan 23rd, 2023


Published on 2024-10-28 01:03:32 - WOPRAI, David Amsellem
  Print publication without navigation


David Amsellem of Piper Sandler, Maintained "Supernus Pharmaceuticals, Inc." (SUPN) at Buy with Increased Target from $40 to $47 on, Jan 23rd, 2023.

David, nor any peers, have made any analyst calls on SUPN in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30

Contributing Sources